GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyclo Therapeutics Inc (NAS:CYTH) » Definitions » Current Ratio

Cyclo Therapeutics (Cyclo Therapeutics) Current Ratio : 1.01 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Cyclo Therapeutics Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Cyclo Therapeutics's current ratio for the quarter that ended in Mar. 2024 was 1.01.

Cyclo Therapeutics has a current ratio of 1.01. It generally indicates good short-term financial strength.

The historical rank and industry rank for Cyclo Therapeutics's Current Ratio or its related term are showing as below:

CYTH' s Current Ratio Range Over the Past 10 Years
Min: 0.51   Med: 2.46   Max: 13.05
Current: 1.01

During the past 13 years, Cyclo Therapeutics's highest Current Ratio was 13.05. The lowest was 0.51. And the median was 2.46.

CYTH's Current Ratio is ranked worse than
78.25% of 1076 companies
in the Drug Manufacturers industry
Industry Median: 1.87 vs CYTH: 1.01

Cyclo Therapeutics Current Ratio Historical Data

The historical data trend for Cyclo Therapeutics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclo Therapeutics Current Ratio Chart

Cyclo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.26 3.83 5.07 1.19 1.45

Cyclo Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 0.75 0.83 1.45 1.01

Competitive Comparison of Cyclo Therapeutics's Current Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Cyclo Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclo Therapeutics's Current Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyclo Therapeutics's Current Ratio distribution charts can be found below:

* The bar in red indicates where Cyclo Therapeutics's Current Ratio falls into.



Cyclo Therapeutics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Cyclo Therapeutics's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=12.318/8.468
=1.45

Cyclo Therapeutics's Current Ratio for the quarter that ended in Mar. 2024 is calculated as

Current Ratio (Q: Mar. 2024 )=Total Current Assets (Q: Mar. 2024 )/Total Current Liabilities (Q: Mar. 2024 )
=6.57/6.536
=1.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyclo Therapeutics  (NAS:CYTH) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Cyclo Therapeutics Current Ratio Related Terms

Thank you for viewing the detailed overview of Cyclo Therapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclo Therapeutics (Cyclo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6714 North West 16th Street, Suite B, Gainesville, FL, USA, 32653
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.
Executives
Vivien Wong director 6C CHATEAUX CIRCLE, SCARSDALE NY 10583
Rafael Holdings, Inc. 10 percent owner 520 BROAD STREET, NEWARK NJ 07120
William Conkling director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Jeffrey Tate director, officer: Chief Executive Officer C/O CTD HOLDINGS, INC., 27317 NW 78TH AVENUE, HIGH SPRINGS FL 32643
Francis Patrick Ostronic director 932 HUNGERFORD DRIVE, SUITE 28A, ROCKVILLE MD 20850
Markus Sieger director BEUTSTWEG 12, CH-8032, ZURICH V8 000000000
N Scott Fine director 600 3RD AVE, NEW YORK NY 10016
Sharon Hemond Hrynkow officer: SVP for Medical Affairs 4816 KING SOLOMON DRIVE, ANNADALE VA 22003
Lise Lund Kjems officer: Chief Medical Officer 91 ROLLINGWOOD LN., CONCORD MA 01742
Joshua M Fine officer: Chief Financial Officer 21 HEMMELSKAMP ROAD, WILTON CT 06897
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Michael Eric Lisjak officer: Chief Regulatory Officer 12 ROOSEVELT AVENUE, OLD GREENWICH CT 06870
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
L.p. Novit, 10 percent owner 966 HUNGERFORD DRIVE, ROCKVILLE MD 20850

Cyclo Therapeutics (Cyclo Therapeutics) Headlines